Related Company:
Vermont Business Magazine In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support such as the need for ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world. Dr Mary Cushman, at the University of Vermont s Larner College of Medicine, is a lead investigator on one aspect of the trial. The trial does not include any Vermont patients.